Research Topics
Species | Richard NashSummaryAffiliation: Fred Hutchinson Cancer Research Center Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donorsR A Nash
Clinical Research Division, Fred Hutchinson Cancer Research Center, and the Department of Medicine, University of Washington, Seattle, WA, USA
Blood 96:2062-8. 2000....- Effect of c-mpl ligands after total body irradiation (TBI) with and without allogeneic hematopoietic stem cell transplantation: low-dose TBI does not prevent sensitizationRichard A Nash
Biol Blood Marrow Transplant 8:360-7. 2002..The significant effect that rhTPO-specific antibodies had on the platelet counts may limit the clinical role of recombinant c-mpl ligands unless sensitization can be prevented... 
High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosisRichard A Nash
Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D1 100, PO Box 19024, Seattle, WA 98109 1024, USA
Blood 102:2364-72. 2003..This was a heterogeneous high-risk group, and a phase 3 study is planned to fully assess efficacy...- Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseasesRichard A Nash
Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
Biol Blood Marrow Transplant 9:583-91. 2003..The differences between equine and rabbit ATG are not yet clearly defined, and they should not be considered interchangeable in this regimen without further study... - Allogeneic marrow transplantation in patients with severe systemic sclerosis: resolution of dermal fibrosisRichard A Nash
Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Arthritis Rheum 54:1982-6. 2006..To evaluate the safety and efficacy of allogeneic hematopoietic cell transplantation (HCT) after myeloablative conditioning in patients with severe systemic sclerosis (SSc)... - High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot studyRichard A Nash
Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
Blood 110:1388-96. 2007..Sustained responses including a decrease in dermal fibrosis were observed exceeding those previously reported with other therapies. HDIT and autologous HCT for SSc should be evaluated in a randomized clinical trial... - Graft-versus-host effect after allogeneic hematopoietic stem cell transplantation: GVHD and GVLR A Nash
Fred Hutchinson Cancer Research Center, Seattle, WA 98104, USA
Curr Opin Immunol 8:674-80. 1996.... - Immunomodulatory effects of mixed hematopoietic chimerism: immune tolerance in canine model of lung transplantationR A Nash
Fred Hutchinson Cancer Research Center, bUniversity of Washington School of Medicine, Seattle, WA, USA
Am J Transplant 9:1037-47. 2009..Establishing MC is immunomodulatory and observed changes were consistent with activation of both the effector and regulatory immune response... - Early recovery of CD4 T cell receptor diversity after "lymphoablative" conditioning and autologous CD34 cell transplantationJan Storek
Fred Hutchinson Cancer Research Center and University of Washington, Seattle, Washington, USA
Biol Blood Marrow Transplant 14:1373-9. 2008..Thus, the therapy may not be completely T cell lymphoablative... - Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effectsP A McSweeney
Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, WA, USA
Blood 97:3390-400. 2001..Future protocol modifications should reduce rejection and GVHD, thereby facilitating studies of allogeneic immunotherapy for a variety of malignancies. (Blood. 2001;97:3390-3400).. - Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantationV Ratanatharathorn
University of Michigan, Ann Arbor Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Blood 92:2303-14. 1998..The survival disadvantage in advanced disease patients receiving tacrolimus warrants further investigation... - IL-2 does not enhance the conversion to complete donor chimerism following nonmyeloablative hematopoietic cell transplantation in dogsG E Georges
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA
Bone Marrow Transplant 31:1027-31. 2003..These results show that IL-2 given with DLI after nonmyeloablative transplantation in dogs is not effective in reliably converting mixed to complete donor chimerism... - Lentiviral vector conferring resistance to mycophenolate mofetil and sensitivity to ganciclovir for in vivo T-cell selectionD Sangiolo
Transplantation Biology, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
Gene Ther 14:1549-54. 2007..The expression of IMPDH(IY) would allow in vivo selection with MMF, and DeltaCD34/TK expression would allow rapid and safe elimination of transduced T cells if graft-versus-host disease developed... - Administration of cyclosporine for 24 months compared with 6 months for prevention of chronic graft-versus-host disease: a prospective randomized clinical trialE Kansu
Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
Blood 98:3868-70. 2001..76; 95% confidence interval, 0.48-1.21; P =.25). In addition, there were no significant differences between the 2 groups in transplantation-related mortality, survival, or disease-free survival... - Purified canine CD34+Lin- marrow cells transduced with retroviral vectors give rise to long-term multi-lineage hematopoiesisB Bruno
Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington Medical School, Seattle, USA
Biol Blood Marrow Transplant 7:543-51. 2001..Whereas canine CD34+Lin- marrow cells contributed to long-term multilineage hematopoiesis, progeny of CD34-Lin- progenitor cells were not detected after transplantation in these experiments... - Molecular cloning and in vivo evaluation of canine granulocyte-macrophage colony-stimulating factorR A Nash
Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98104
Blood 78:930-7. 1991..Evaluation of survival times of 51Cr-labeled autologous platelets suggested increased consumption as the primary reason for thrombocytopenia. A species-specific GM-CSF will be a useful tool for hematologic or immunologic studies in dogs... - A proposed objective way to assess results of randomized prospective clinical trials with acute graft-versus-host disease as an outcome of interestH Al-Ghamdi
Division of Clinical Research, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA
Br J Haematol 113:461-9. 2001..Further studies will be needed to determine if similar methods could be used in randomized clinical trials for prevention of GVHD... - Assessment of myocardial hypertrophy by echocardiography in adult patients receiving tacrolimus or cyclosporine therapy for prevention of acute GVHDG Espino
Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, Seattle, WA 98109-1024, USA
Bone Marrow Transplant 28:1097-103. 2001..The increase in LVMI after transplant in the cyclosporine group was greater than in the tacrolimus group but was not associated with any significant clinical events... - Allogeneic HSCT for autoimmune diseases: conventional conditioning regimensR A Nash
Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D1-100, PO Box 19024, Seattle, Washington 98109-1024, USA
Bone Marrow Transplant 32:S77-80. 2003.... - Optimizing a canine survival model of orthotopic lung transplantationA S Farivar
University of Washington Medical Center, Division of Cardiothoracic Surgery, Seattle, Washington 98195, USA
Transplant Proc 38:1638-40. 2006..Herein, we describe optimization of a canine survival model of orthotopic lung transplantation... - Adoptive immunotherapy in canine mixed chimeras after nonmyeloablative hematopoietic cell transplantationG E Georges
Clinical Research Division, Fred Hutchinson Cancer Research Center, Department of Medicine, University of Washington, Seattle, WA 98109 1024, USA
Blood 95:3262-9. 2000..We propose that mixed chimerism established after nonmyeloablative allogeneic stem-cell transplantation provides a platform for adoptive immunotherapy that has clinical potential in the treatment of patients with malignant diseases... - Unrelated and HLA-nonidentical related donor marrow transplantation for thalassemia and leukemia. A combined report from the Seattle Marrow Transplant Team and the International Bone Marrow Transplant RegistryK M Sullivan
Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
Ann N Y Acad Sci 850:312-24. 1998..Using the paradigm of CML, it is likely that access to curative therapy of thalassemia will improve with optimal HLA typing and donor selection early in the course of disease... - Polyclonal hematopoiesis with variable telomere shortening in human long-term allogeneic marrow graft recipientsG Mathioudakis
Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
Blood 96:3991-4. 2000..These data suggest that under standard transplantation conditions, the stem cell proliferative potential is not compromised during hematopoietic reconstitution. (Blood. 2000;96:3991-3994).. - Current and future preparative regimens for bone marrow transplantation in thalassemiaR Storb
Transplantation Biology Program, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
Ann N Y Acad Sci 850:276-87. 1998..Mixed donor/host chimerism (> or = 50% donor cells in all lineages) has persisted for > 80 weeks, even though immunosuppression was discontinued after five weeks... - Mixed hematopoietic chimerism after marrow allografts. Transplantation in the ambulatory care settingR Storb
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
Ann N Y Acad Sci 872:372-5; discussion 375-6. 1999..This paper describes the development of nonmyeloablative marrow transplant programs that have little toxicity in a canine model and their translation to patients with malignant and nonmalignant hematological diseases... - Nonmyeloablative hematopoietic stem cell transplantation: transplantation for the 21st centuryM Maris
Fred Hutchinson Cancer Research Center, University of Washington, Seattle 98109-1024, USA
Front Biosci 6:G13-6. 2001.... - Therapy with mycophenolate mofetil for refractory acute and chronic GVHDT Furlong
Division of Clinical Research, Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, 1100 Fairview Avenue N, Seattle, WA 98109, USA
Bone Marrow Transplant 44:739-48. 2009..The area under the curve plasma concentrations of mycophenolic acid seemed to be suboptimal among patients with acute GVHD but not among those with chronic GVHD. MMF can be used effectively for treatment of GVHD... - Nonmyeloablative hematopoietic cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effectL Feinstein
Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, D1 100, P O Box 19024, Seattle, Washington 98109 1024, USA
Ann N Y Acad Sci 938:328-37; discussion 337-9. 2001..Remissions occurred gradually over periods of weeks to a year. If long-term efficacy is demonstrated, such a strategy would expand treatment options for patients who would otherwise be excluded from conventional allografting... - Engraftment of DLA-haploidentical marrow with ex vivo expanded, retrovirally transduced cytotoxic T lymphocytesG E Georges
Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington, Seattle 98109, USA
Blood 98:3447-55. 2001..These results show that ex vivo expanded, transduced T cells maintained in vivo function and enhanced marrow engraftment... - Immunity of patients surviving 20 to 30 years after allogeneic or syngeneic bone marrow transplantationJ Storek
Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA, USA
Blood 98:3505-12. 2001..Patients who received transplants in adulthood have a clinically insignificant deficiency of de novo-generated CD4 T cells, suggesting that in these patients the posttransplantation thymic insufficiency may not be fully reversible... - Survival of small bowel transplants in canine mixed hematopoietic chimeras: preliminary resultsM Y Yunusov
Clinical Research Division, Fred Hutchinson Cancer Research Center, Department of Medicine, University of Washington School of Medicine, Seattle, Washington 98109, USA
Transplant Proc 34:3366-7. 2002 - Antagonistic and agonistic anti-canine CD28 monoclonal antibodies: tools for allogeneic transplantationScott S Graves
Transplantation Biology Program, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
Transplantation 91:833-40. 2011..This is based on the premise that specifically blocking CD28 allows inhibitory signals through CTLA-4 to proceed, which furthermore suppresses T-cell function... - A limited sampling schedule to estimate mycophenolic Acid area under the concentration-time curve in hematopoietic cell transplantation recipientsHong Li
Department of Pharmacy, Box 357630, University of Washington, Seattle, WA 98195, USA
J Clin Pharmacol 52:1654-64. 2012..5, 3, 5, and 6 hours from the start of the infusion precisely estimated MPA AUC(0-12 h) for Q12-hour IV MMF. A comparable schedule (2, 2.5, 3, 4, and 6 hours) similarly estimated MPA AUC(0-8) (h) for Q8-hour dosing... - Identification and characterization of canine dendritic cells generated in vivoMarco Mielcarek
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
Biol Blood Marrow Transplant 13:1286-93. 2007..In summary, CD11c+/HLA-DR+/CD14-/DM5- cells obtained from canine peripheral blood have functional and morphologic characteristics similar to those of human myeloid DC... - Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host diseaseA I Benito
Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave, North, D1-100, P.O. Box 19204, Seattle, WA 98109-1204, USA
Transplantation 72:1924-9. 2001..CONCLUSION: These data suggest that sirolimus has activity in the treatment of steroid-refractory acute GVHD. However, there was considerable toxicity and further dose optimization studies seem warranted... - Secondary failure of platelet recovery after hematopoietic stem cell transplantationB Bruno
The Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington Medical School, Seattle 98109-1024, USA
Biol Blood Marrow Transplant 7:154-62. 2001..The identification of the characteristics and risk factors for SFPR could improve patient counseling and management and lead to the design of effective treatment strategies... - Toxicity and efficacy of daily dapsone as Pneumocystis jiroveci prophylaxis after hematopoietic stem cell transplantation: a case-control studyDario Sangiolo
Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024, USA
Biol Blood Marrow Transplant 11:521-9. 2005..Further studies are required to establish whether the drug has an etiologic role in these situations... - Canine CD34: cloning of the cDNA and evaluation of an antiserum to recombinant proteinP A McSweeney
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98104, USA
Blood 88:1992-2003. 1996.... - Molecular cloning of the CD3 epsilon subunit of the T-cell receptor/CD3 complex in dogR A Nash
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98104
Immunogenetics 33:396-8. 1991 - Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimenH Joachim Deeg
Fred Hutchinson Cancer Research Center and University of Washington School of Medicine, Seattle, Washington 98109 1024, USA
Biol Blood Marrow Transplant 12:573-84. 2006.... - Intussusception in canine recipients of hematopoietic cell grafts and surgical correctionMurad Y Yunusov
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Comp Med 57:287-91. 2007..Intussusception did not recur after surgical intervention in any dog. Recent HCT and post-transplant immunosuppressive therapy are not absolute contraindications to surgical intervention for intussusception in canine recipients of HCT... - Pitfalls in the design of clinical trials for prevention or treatment of acute graft-versus-host diseasePaul J Martin
Division of Clinical Research, Fred Hutchinson Cancer Research Center and Department of Medicine, University of Washington, Seattle, Washington 98109 1024, USA
Biol Blood Marrow Transplant 12:31-6. 2006..Finally, investigators should be aware of regulatory and socioeconomic pitfalls that apply to all clinical trials... - Target populations in allogeneic hematopoietic cell transplantation for autoimmune diseases--a workshop accompanying: cellular therapy for treatment of autoimmune diseases, basic science and clinical studies, including new developments in hematopoietic anLinda M Griffith
Biol Blood Marrow Transplant 12:688-90. 2006 - Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donorsTerry Furlong
Division of Clinical Research, Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, WA 98109 1024, USA
Biol Blood Marrow Transplant 14:531-7. 2008..In these studies, the addition of sirolimus to regimens containing a calcineurin inhibitor and methotrexate appeared to cause toxicity and provided no detectable improvement in preventing GVHD... - Normal interleukin-7 (IL7) levels and normal IL7 response to CD4 T lymphopenia in patients with multiple sclerosis and systemic sclerosisJan Storek
Clin Immunol 121:118-9. 2006 - Partial donor-specific tolerance to delayed skin grafts after rejection of hematopoietic cell graftMurad Y Yunusov
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Transplantation 82:629-37. 2006..Partial DST can persist after HC graft rejection even if solid organ transplantation is delayed. Further investigations are required to understand the mechanisms responsible for DST after allogeneic HCT... - Cyclophosphamide in scleroderma lung diseaseKeith M Sullivan
N Engl J Med 355:1173-4; author reply 1174. 2006 - Autologous HSCT for advanced MS: is the glass half-empty or really half-full?Richard A Nash
Brain 131:e89; author reply e90. 2008 - Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic dChunkang Chang
Department of Hematology, Shanghai Sixth People s Hospital, Shanghai Jiaotong University, Shanghai, People s Republic of China
Blood 110:1379-87. 2007..The data suggest that overall inferior outcome in patients with secondary MDS/tAML was related to the frequency of high-risk cytogenetics. For both cohorts, transplantation outcomes improved over the time interval studied... - Feasibility of allogeneic hematopoietic stem cell transplantation for autoimmune disease: position statement from a National Institute of Allergy and Infectious Diseases and National Cancer Institute-Sponsored International Workshop, Bethesda, MD, March 1Linda M Griffith
Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
Biol Blood Marrow Transplant 11:862-70. 2005 - Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantationLuisa Giaccone
Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D1-100, PO Box 19024, Seattle, WA 98109-1024, USA
Blood 106:4381-8. 2005..We conclude that increased MPA Css's predicted higher degrees of donor T-cell chimerism after unrelated donor nonmyeloablative HCT and suggest that targeting MPA Css's greater than 2.5 microg/mL could prevent graft rejection... - Minor histocompatibility antigen-specific cytotoxic T lymphocytes generated with dendritic cells from DLA-identical littermatesGeorge E Georges
Department of Medicine, University of Washington, Seattle, Washington 98109 1024, USA
Biol Blood Marrow Transplant 9:234-42. 2003..We conclude that after recent in vivo sensitization, large-scale ex vivo expansion of mHA-specific CTL was feasible using allogeneic DCs... - FLT3 ligand promotes engraftment of allogeneic hematopoietic stem cells without significant graft-versus-host diseaseMurad Y Yunusov
Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, Seattle, WA 98109, USA
Transplantation 75:933-40. 2003..CONCLUSIONS: In this study, the authors showed that FL administered to recipients promotes stable engraftment of allogeneic marrow from DLA-identical littermates after 4.5 Gy TBI without significant GVHD... - NOD/SCID mice transplanted with marrow from patients with myelodysplastic syndrome (MDS) show long-term propagation of normal but not clonal human precursorsAna I Benito
Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, D1-100, P.O. Box 19024, Seattle, WA 98109-1204, USA
Leuk Res 27:425-36. 2003..This model may allow identification of factors relevant for sustaining or expanding clonal precursors... - High-dose cyclophosphamide in multiple sclerosis patients undergoing autologous stem cell transplantationTimothy R McGuire
Department of Pharmacy Practice, University of Nebraska Medical Center, 986045, Omaha, NE 68198 6045, USA
Int Immunopharmacol 3:279-83. 2003..In conclusion, in this small case series, there was no indication that CTX metabolism was different than that in other populations undergoing transplantation... - Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortalityManuel Jurado
Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024, USA
Biol Blood Marrow Transplant 8:161-9. 2002..Future trials should explore the efficacy and tolerability of reduced-intensity conditioning regimens... - High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomesPeter A McSweeney
University of Colorado Health Sciences Center, Denver 80262, USA
Blood 100:1602-10. 2002..Responses in skin and mHAQ-DI scores exceed those reported with other therapies, suggesting that HDIT is a promising new therapy for SSc that should be evaluated in prospective randomized studies... - Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone aloneSibel Koc
Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
Blood 100:48-51. 2002.... - High-dose immunosuppression and hematopoietic stem cell transplantation in autoimmune disease: clinical reviewHarry Openshaw
City of Hope National Medical Center, Duarte, California 91010, USA
Biol Blood Marrow Transplant 8:233-48. 2002..Parallel trials in Europe and in the United States are in the late stages of design... - Psoralen and ultraviolet A irradiation (PUVA) as therapy for steroid-resistant cutaneous acute graft-versus-host diseaseTerry Furlong
Fred Hutchinson Cancer Research Center, and the Department of Medicine, University of Washington, Seattle 98109 1024, USA
Biol Blood Marrow Transplant 8:206-12. 2002..Fifty-three patients (51%) remain alive at 129-1883 days after transplantation. These results suggest that PUVA can be an effective therapy for steroid-resistant acute GVHD of the skin... - Recombinant human macrophage colony-stimulating factor-induced thrombocytopenia in dogsKraig Abrams
Puget Sound Blood Center, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98109-1024, USA
Br J Haematol 121:614-22. 2003..18; n = 4). These results support the concept that rhM-CSF induces an activation of the monocyte-macrophage system (MMS), which causes a reversible TCP in a dog model... - Adoptive immunotherapy to increase the level of donor hematopoietic chimerism after nonmyeloablative marrow transplantation for severe canine hereditary hemolytic anemiaAlessandra Takatu
Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024, USA
Biol Blood Marrow Transplant 9:674-82. 2003..We conclude that DLI after nonmyeloablative HCT can increase the levels of donor cells contributing to hematopoiesis in recipients, inducing remissions of the hemolytic process and preventing complications associated with iron overload... - A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantationRichard A Nash
Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
Biol Blood Marrow Transplant 11:495-505. 2005..Although a significant improvement in the prevention of GVHD was not suggested, compared with CSP and MTX, MMF in combination with CSP could be considered in cases in which MTX is contraindicated... - Recovery from and consequences of severe iatrogenic lymphopenia (induced to treat autoimmune diseases)Jan Storek
Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA 98109 1024, USA
Clin Immunol 113:285-98. 2004..In conclusion, peripheral expansion of CD8 but not CD4 T cells is highly efficient. Prolonged CD4 lymphopenia is associated with relatively few infections, possibly due to antibodies produced by persisting pretransplant plasma cells... - Novel approaches to the therapy of steroid-resistant acute graft-versus-host diseaseJoseph H Antin
Dana-Farber Cancer Institute, Boston, Massachusetts, USA
Biol Blood Marrow Transplant 10:655-68. 2004 - Duration of immunosuppressive treatment for chronic graft-versus-host diseaseBetty L Stewart
Division of Clinical Research, Fred Hutchinson Cancer Research Center, PO Box 19024, Seattle, WA 98109, USA
Blood 104:3501-6. 2004..After the dose of prednisone was taken into account, progressive onset was not associated with an increased risk of nonrelapse mortality... - Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantationPaul J Martin
Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
Biol Blood Marrow Transplant 10:552-60. 2004.... - Isolation and characterization of pediatric canine bone marrow CD34+ cellsSteven E Suter
Section of Medical Genetics, Department of Clinical Studies, University of Pennsylvania School of Veterinary Medicine, 3900 Delancey St, Philadelphia 19104, USA
Vet Immunol Immunopathol 101:31-47. 2004.... - Discordant functional and inflammatory parameters in multiple sclerosis patients after autologous haematopoietic stem cell transplantationKathleen M Healey
Department of Neurological Sciences, University of Nebraska Medical Center, Omaha, NE, USA
Mult Scler 10:284-9. 2004..The results demonstrate however, a dissociation of inflammation parameters and functional disability findings raising questions about optimal future stem cell transplantation strategies for this disease... - Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantationPaul J Martin
Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
Biol Blood Marrow Transplant 10:320-7. 2004..A high diagnostic sensitivity and increased awareness that gut GVHD can occur without skin involvement account for the increased incidence of acute GVHD at our center... - Transplantation of X-linked severe combined immunodeficient dogs with CD34+ bone marrow cellsBrian J Hartnett
Department of Clinical Studies, School of Veterinary Medicine, University of Pennsylvania, Philadelphia 19104, USA
Biol Blood Marrow Transplant 8:188-97. 2002.... - Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventionsOlaf Stuve
Neurology Section, Medical Service, Veterans Affairs North Texas Health Care System, Dallas, TX, USA
Arch Neurol 64:169-76. 2007..Because it is currently impossible to identify patients at risk, and thus to prevent PML as a consequence of natalizumab therapy, it is important that neurologists be aware of possible therapeutic interventions...
Research Grants
- Lung Transplantation and Immune Tolerance in Young RecipientsRichard Nash; Fiscal Year: 2007..Development of preclinical strategies for the induction of lung-specific tolerance in large animal models to prevent acute and chronic rejection will increase the probability of successful translation to human studies. ..
- Protection from GVHD with Gene-Modified Donor T CellsRichard Nash; Fiscal Year: 2007....
- Nonmyeloablative Hematopoietic Cell Transplantation for Severe Systemic SclerosisRichard Nash; Fiscal Year: 2006..The unique observations in this study regarding responses and recovery of organs after inducing a sustained remission of SSc will serve to focus and direct other non-transplant research activities. ..
- HEMATOPOIETIC GROWTH FACTORS IN A CANINE STEM CELL MODELRichard Nash; Fiscal Year: 2003....
- ENGRAFTING SENSITIZED HOSTS WITH NONABLATIVE REGIMENSRichard Nash; Fiscal Year: 2002..By lessening the morbidity and mortality associated with conventional conditioning, these studies could significantly change the management of selected inherited red blood cell diseases. ..